title: Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer.
abstract: OBJECTIVE
  To investigate whether unilaterally orchiectomised testicular cancer survivors (TCSs) are more likely to display reduced Leydig cell function than healthy males.
  
  
  METHODS
  A national multi-centre survey of 1235 TCSs was performed in 1998-2000 (mean age: 44 years) treated between 1980 and 1994 (mean follow-up: 11 years). Serum hormone analyses were performed on 1183 TCSs, as 52 TCSs used androgen replacement (AR). TCSs were allocated to four treatment groups: Surgery only (251); Radiotherapy only (515); Chemotherapy 1, cisplatin </=850 mg (373); Chemotherapy 2, cisplatin >850 mg (96). The Controls were represented by 200 healthy blue-collar workers (mean age: 44 years). LH >12 IU/l and testosterone <8 nmol/l and the use of AR indicated hypogonadism.
  
  
  RESULTS
  Serum testosterone was similar in TCSs and Controls (16.9 vs.17.1 nmol/l), but TCSs had higher age-adjusted LH levels than the Controls (5.2 vs. 3.5 IU/l). LH increased with treatment intensity, but was elevated even in TCSs treated with surgery only. The age-adjusted odds ratio of hypogonadism was 3.8 (95%CI: 2.0-7.3) in TCSs, and increased with treatment intensity.
  
  
  CONCLUSIONS
  TCSs are at risk to develop pre-mature reduced Leydig cell function and hypogonadism. They may therefore be predisposed for the syndrome of androgen deficiency of aging males (ADAM).
authors.affiliation: Department of Clinical Research, The Norwegian Radiumhospital, University Hospital, Montebello, 0310, Oslo, Norway. carina.nord@klinmed.uio.no
authors.forename: Carina
authors.initials: C
authors.lastname: Nord
authors.forename: Trine
authors.initials: T
authors.lastname: Bjøro
authors.forename: Dag
authors.initials: D
authors.lastname: Ellingsen
authors.forename: Arnstein
authors.initials: A
authors.lastname: Mykletun
authors.forename: Olav
authors.initials: O
authors.lastname: Dahl
authors.forename: Olbjørn
authors.initials: O
authors.lastname: Klepp
authors.forename: Roy M
authors.initials: RM
authors.lastname: Bremnes
authors.forename: Erik
authors.initials: E
authors.lastname: Wist
authors.forename: Sophie D
authors.initials: SD
authors.lastname: Fosså
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D016022:Case-Control Studies; D015897:Comorbidity; D042341:Gonadal Hormones / Q000097:blood*; D006801:Humans; D007006:Hypogonadism / Q000453:epidemiology; D016015:Logistic Models; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D009664:Norway / Q000453:epidemiology; D011159:Population Surveillance; D012016:Reference Values; D017741:Survivors / Q000706:statistics & numerical data*; D013736:Testicular Neoplasms / Q000097:blood* / Q000453:epidemiology* / Q000628:therapy; D013739:Testosterone / Q000097:blood
chemical_list: D042341:Gonadal Hormones; D013739:Testosterone; D007986:Luteinizing Hormone